TapewireFind a company

person · Reporting owner

Jacobson Mark L.

Disclosed activity across 1 company

Tapewire entity
2470
SEC CIK
0001805812

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Axsome Therapeutics, Inc.AXSM · Entity 2469Chief Operating OfficerSeptember 03, 2026September 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Axsome Therapeutics, Inc.

Report date September 03, 2026 · Filed September 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2026-09-03 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-03 · Exercise / conversion · Acquired 10,000 · Balance 10,000

F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Row 2 · 2026-09-03 · Sale · Disposed 10,000 · Balance 0

F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.95 · Expires 2029-03-19Direct104,954 Reported balance After 2026-09-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-09-03 · Exercise / conversion · Disposed 10,000 · Balance 104,954

F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 03, 2026 Filed Sep 3, 2026 23:09 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $12.95 $0.00
Disclosure

SEC source: 0001193125-26-382277 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,954

Underlying: Common Stock · 10,000 shares

Expires 2029-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
September 03, 2026 Filed Sep 3, 2026 23:09 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 10,000 $208.65 $2,086,500.00
Disclosure

SEC source: 0001193125-26-382277 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.

Read SEC document
September 03, 2026 Filed Sep 3, 2026 23:09 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 10,000 $12.95 $129,500.00
Disclosure

SEC source: 0001193125-26-382277 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
May 05, 2026 Filed May 6, 2026 00:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 233 $0.00 Strike: $12.95 $0.00
Disclosure

SEC source: 0001193125-26-207148 · ownership.xml · derivative · entry 6

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,954

Underlying: Common Stock · 233 shares

Expires 2029-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Read SEC document
May 05, 2026 Filed May 6, 2026 00:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 233 $228.18 $53,165.94
Disclosure

SEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 4

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77.

Read SEC document
May 05, 2026 Filed May 6, 2026 00:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 233 $12.95 $3,017.35
Disclosure

SEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Read SEC document
May 04, 2026 Filed May 6, 2026 00:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 4,517 $0.00 Strike: $12.95 $0.00
Disclosure

SEC source: 0001193125-26-207148 · ownership.xml · derivative · entry 5

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,187

Underlying: Common Stock · 4,517 shares

Expires 2029-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Read SEC document
May 04, 2026 Filed May 6, 2026 00:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 4,517 $227.94 $1,029,604.98
Disclosure

SEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97.

Read SEC document
May 04, 2026 Filed May 6, 2026 00:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 4,517 $12.95 $58,495.15
Disclosure

SEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,517

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

Read SEC document
April 21, 2026 Filed Apr 24, 2026 01:02 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantPerformance Stock Units · Derivative 8,669 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-174419 · ownership.xml · derivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,669

Underlying: Common Stock · 8,669 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

F2 · derivative.expiration_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Read SEC document
February 26, 2026 Filed Feb 28, 2026 00:10 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantRestricted Stock Units · Derivative 19,663 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-083605 · ownership.xml · derivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,663

Underlying: Common Stock · 19,663 shares

Expires 2036-02-26

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.

Read SEC document
February 26, 2026 Filed Feb 28, 2026 00:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 35,378 $0.00 Strike: $2.85 $0.00
Disclosure

SEC source: 0001193125-26-083586 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,378 shares

Expires 2028-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
February 26, 2026 Filed Feb 28, 2026 00:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 35,378 $161.88 $5,726,990.64
Disclosure

SEC source: 0001193125-26-083586 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.10 and $163.42.

Read SEC document
February 26, 2026 Filed Feb 28, 2026 00:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 35,378 $2.85 $100,827.30
Disclosure

SEC source: 0001193125-26-083586 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,378

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
September 22, 2025 Filed Sep 22, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $2.85 $0.00
Disclosure

SEC source: 0001193125-25-211788 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,378

Underlying: Common Stock · 10,000 shares

Expires 2028-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.

Read SEC document
September 22, 2025 Filed Sep 22, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 10,000 $115.96 $1,159,600.00
Disclosure

SEC source: 0001193125-25-211788 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $115.11 and $116.55.

Read SEC document
September 22, 2025 Filed Sep 22, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 10,000 $2.85 $28,500.00
Disclosure

SEC source: 0001193125-25-211788 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $4.85 $0.00
Disclosure

SEC source: 0001193125-25-206494 · ownership.xml · derivative · entry 6

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2027-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $4.95 $0.00
Disclosure

SEC source: 0001193125-25-206494 · ownership.xml · derivative · entry 5

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 40,000 $114.23 $4,569,200.00
Disclosure

SEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 4

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F4 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $112.93 and $116.87.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 15,000 $4.85 $72,750.00
Disclosure

SEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 25,000 $4.95 $123,750.00
Disclosure

SEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 5,783 $116.19 $671,926.77
Disclosure

SEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Represents the sale of underlying shares of previously exercised stock options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F5 · price: Represents the sale price of all shares in an open market transaction.

Read SEC document
June 09, 2025 Filed Jun 10, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $8.02 $0.00
Disclosure

SEC source: 0000950170-25-084556 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2026-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
June 09, 2025 Filed Jun 10, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 25,000 $110.44 $2,761,000.00
Disclosure

SEC source: 0000950170-25-084556 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,783

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24.

Read SEC document
June 09, 2025 Filed Jun 10, 2025 23:00 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 25,000 $8.02 $200,500.00
Disclosure

SEC source: 0000950170-25-084556 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
May 28, 2025 Filed May 29, 2025 01:52 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $6.47 $0.00
Disclosure

SEC source: 0000950170-25-078552 · ownership.xml · derivative · entry 6

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2025-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
May 28, 2025 Filed May 29, 2025 01:52 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 20,000 $103.45 $2,069,000.00
Disclosure

SEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 4

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,783

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.67 and $104.22.

Read SEC document
May 28, 2025 Filed May 29, 2025 01:52 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 20,000 $6.47 $129,400.00
Disclosure

SEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
May 27, 2025 Filed May 29, 2025 01:52 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 20,673 $0.00 Strike: $6.47 $0.00
Disclosure

SEC source: 0000950170-25-078552 · ownership.xml · derivative · entry 5

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,673 shares

Expires 2025-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
May 27, 2025 Filed May 29, 2025 01:52 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 20,673 $104.66 $2,163,636.18
Disclosure

SEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,783

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $103.96 and $106.44.

Read SEC document
May 27, 2025 Filed May 29, 2025 01:52 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 20,673 $6.47 $133,754.31
Disclosure

SEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,456

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
February 24, 2025 Filed Feb 26, 2025 00:53 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantPerformance Stock Units · Derivative 10,769 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-027065 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,769

Underlying: Common Stock · 10,769 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date.

F5 · derivative.expiration_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date.

Read SEC document
February 21, 2025 Filed Feb 26, 2025 00:53 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantRestricted Stock Units · Derivative 10,769 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-027065 · ownership.xml · derivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,769

Underlying: Common Stock · 10,769 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

Read SEC document
February 21, 2025 Filed Feb 26, 2025 00:53 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantEmployee Stock Option (Right to Buy) · Derivative 10,875 $0.00 Strike: $137.75 $0.00
Disclosure

SEC source: 0000950170-25-027065 · ownership.xml · derivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,875

Underlying: Common Stock · 10,875 shares

Expires 2035-02-20

F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 21, 2029.

Read SEC document
August 09, 2024 Filed Aug 9, 2024 23:27 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 47,739 $0.00 Strike: $4.04 $0.00
Disclosure

SEC source: 0000950170-24-094967 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 47,739 shares

Expires 2024-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this year.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
August 09, 2024 Filed Aug 9, 2024 23:27 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 47,739 $84.26 $4,022,488.14
Disclosure

SEC source: 0000950170-24-094967 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,783

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $82.705 and $85.975.

Read SEC document
August 09, 2024 Filed Aug 9, 2024 23:27 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 47,739 $4.04 $192,865.56
Disclosure

SEC source: 0000950170-24-094967 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,522

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this year.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
May 29, 2024 Filed May 30, 2024 00:12 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 13,693 $0.00 Strike: $1.30 $0.00
Disclosure

SEC source: 0000950170-24-066177 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,693 shares

Expires 2024-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options.

Read SEC document
May 29, 2024 Filed May 30, 2024 00:12 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 7,910 $74.31 $587,813.46
Disclosure

SEC source: 0000950170-24-066177 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

F2 · kind: Represents the subsequent sale of a portion of the underlying shares of the aforementioned exercise of stock options by the reporting person through a "sell to cover" transaction to satisfy tax withholding obligations and costs in connection with the aforementioned exercise of stock options.

F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $73.99 and $74.52.

Read SEC document
May 29, 2024 Filed May 30, 2024 00:12 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 13,693 $1.30 $17,800.90
Disclosure

SEC source: 0000950170-24-066177 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options.

Read SEC document
April 01, 2024 Filed Apr 1, 2024 22:46 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionStock Option (Right to Buy) · Derivative 24,662 $0.00 Strike: $1.30 $0.00
Disclosure

SEC source: 0000950170-24-039617 · ownership.xml · derivative · entry 3

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,662 shares

Expires 2024-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options immediately prior to the 10-year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
April 01, 2024 Filed Apr 1, 2024 22:46 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 SaleCommon Stock 24,662 $77.24 $1,904,942.20
Disclosure

SEC source: 0000950170-24-039617 · ownership.xml · nonDerivative · entry 2

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

Read SEC document
April 01, 2024 Filed Apr 1, 2024 22:46 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 Exercise / conversionCommon Stock 24,662 $1.30 $32,060.60
Disclosure

SEC source: 0000950170-24-039617 · ownership.xml · nonDerivative · entry 1

Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,662

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an exercise of stock options immediately prior to the 10-year expiration date of such options.

F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantRestricted Stock Units · Derivative 18,027 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-023373 · ownership.xml · derivative · entry 2

Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,027

Underlying: Common Stock · 18,027 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:34 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantEmployee Stock Option (Right to Buy) · Derivative 32,825 $0.00 Strike: $84.00 $0.00
Disclosure

SEC source: 0000950170-24-023373 · ownership.xml · derivative · entry 1

Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,825

Underlying: Common Stock · 32,825 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 27, 2028.

Read SEC document
March 02, 2023 Filed Mar 6, 2023 23:15 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantRestricted Stock Units · Derivative 23,491 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016458 · doc4.xml · derivative · entry 2

Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,491

Underlying: Common Stock · 23,491 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

Read SEC document
March 02, 2023 Filed Mar 6, 2023 23:15 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantEmployee Stock Option (Right to Buy) · Derivative 41,424 $0.00 Strike: $65.32 $0.00
Disclosure

SEC source: 0001209191-23-016458 · doc4.xml · derivative · entry 1

Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,424

Underlying: Common Stock · 41,424 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 2, 2027.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 22:03 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantRestricted Stock Units · Derivative 47,990 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017159 · doc4.xml · derivative · entry 2

Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,990

Underlying: Common Stock · 47,990 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 22:03 UTC Axsome Therapeutics, Inc. AXSM · Entity 2469 GrantEmployee Stock Option (Right to Buy) · Derivative 89,405 $0.00 Strike: $29.91 $0.00
Disclosure

SEC source: 0001209191-22-017159 · doc4.xml · derivative · entry 1

Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,405

Underlying: Common Stock · 89,405 shares

Expires 2032-03-03

F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 4, 2026.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.